Latest Abraxane Stories
Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility.
Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Edward C. Geehr, M.D., has joined the company as Executive Vice President of Operations. Dr.
The National Comprehensive Cancer Network, Abraxis BioScience and AstraZeneca have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anticancer drug Abraxane for injectable suspension, which is based on the company's proprietary tumor targeting technology known as the nab platform.
The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform.
Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.
Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.
- One of a pair of round metal cymbals attached to the fingers and struck together for rhythm and percussion in belly dancing.